Zebrafish as a model to assess cancer heterogeneity, progression and relapse

DMM Disease Models and Mechanisms

Volumn 7, Issue 7, 2014, Pages 755-762

  Blackburn, Jessica S ^a,b   Langenau, David M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Cancer stem cell; Fluorescence; Intratumoral; Single cell; Targeted therapy; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; SHORT HAIRPIN RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIOINFORMATICS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL HETEROGENEITY; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; CRISPR CAS SYSTEM; DNA END JOINING REPAIR; DRUG RESPONSE; GENE MUTATION; GENETIC HETEROGENEITY; HOMOLOGOUS RECOMBINATION; HUMAN; IMAGING; LOSS OF FUNCTION MUTATION; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; RNA EDITING; SPECIES COMPARISON; TRANSGENIC ZEBRAFISH; TRANSGENICS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ZEBRA FISH; ANIMAL; DISEASE COURSE; DISEASE MODEL; GENETICS; NEOPLASM; PATHOLOGY; RECURRENT DISEASE; SPECIES DIFFERENCE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC HETEROGENEITY; HUMANS; NEOPLASMS; RECURRENCE; SPECIES SPECIFICITY; ZEBRAFISH;

EID: 84903997892     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.015842     Document Type: Review

References (75)

1. Almendro, V., Marusyk, A. and Polyak, K. (2013). Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 8, 277-302.
2. Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S. M., Kempski, H., Moorman, A. V., Titley, I., Swansbury, J. et al. (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361.
3. Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S. et al. (2013). Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395-2401.
4. Balciunas, D. and Ekker, S. C. (2005). Trapping fish genes with transposons. Zebrafish 1, 335-341. (Pubitemid 40428695)
5. Bedell, V. M., Wang, Y., Campbell, J. M., Poshusta, T. L., Starker, C. G., Krug, R.G., 2nd, Tan, W., Penheiter, S. G., Ma, A. C., Leung, A. Y. H. et al. (2012). In vivo genome editing using a high-efficiency TALEN system. Nature 491, 114-118.
6. Blackburn, J. S., Liu, S., Raiser, D. M., Martinez, S. A., Feng, H., Meeker, N. D., Gentry, J., Neuberg, D., Look, A. T., Ramaswamy, S. et al. (2012). Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 26, 2069-2078.
7. Blackburn, J. S., Liu, S., Wilder, J. L., Dobrinski, K. P., Lobbardi, R., Moore, F. E., Martinez, S. A., Chen, E. Y., Lee, C. and Langenau, D. M. (2014). Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 25, 366-378.
8. Buob, D., Fauvel, H., Buisine, M.-P., Truant, S., Mariette, C., Porchet, N., Wacrenier, A., Copin, M.-C. and Leteurtre, E. (2012). The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. Dig. Dis. Sci. 57, 1271-1280.
9. Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L. et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113.
10. Castellarin, M., Milne, K., Zeng, T., Tse, K., Mayo, M., Zhao, Y., Webb, J. R., Watson, P. H., Nelson, B. H. and Holt, R. A. (2013). Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J. Pathol. 229, 515-524.
11. Catchen, J. M., Braasch, I. and Postlethwait, J. H. (2011). Conserved synteny and the zebrafish genome. Methods Cell Biol. 104, 259-285.
12. Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F. et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517.
13. Cerrano, M., Crisà, E., Pregno, P., Aguzzi, C., Riccomagno, P., Boccadoro, M. and Ferrero, D. (2013). Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. Am. J. Hematol. 88, 838-842.
14. Chang, N., Sun, C., Gao, L., Zhu, D., Xu, X., Zhu, X., Xiong, J.-W. and Xi, J. J. (2013). Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 23, 465-472.
15. Chen, E. Y., Dobrinski, K. P., Brown, K. H., Clagg, R., Edelman, E., Ignatius, M. S., Chen, J. Y. H., Brockmann, J., Nielsen, G. P., Ramaswamy, S. et al. (2013). Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS Genet. 9, e1003727.
16. Chen, E. Y., Deran, M. T., Ignatius, M. S., Grandinetti, K. B., Clagg, R., McCarthy, K. M., Lobbardi, R. M., Brockmann, J., Keller, C., Wu, X., et al. (2014). Glycogen synthase kinase 3 inhibitors induce the canonical WNT/â-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc. Natl. Acad. Sci. USA [Epub ahead of print] doi:10.1073/pnas.1317731111.
17. Coons, S. W., Johnson, P. C. and Shapiro, J. R. (1995). Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma. Cancer Res. 55, 1569-1577.
18. De Rienzo, G., Gutzman, J. H. and Sive, H. (2012). Efficient shRNA-mediated inhibition of gene expression in zebrafish. Zebrafish 9, 97-107.
19. Diaz, L. A., Jr, Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A. et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540.
20. Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D. et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510.
21. Dong, Z., Peng, J. and Guo, S. (2013). Stable gene silencing in zebrafish with spatiotemporally targetable RNA interference. Genetics 193, 1065-1071.
22. Feng, H., Stachura, D. L., White, R. M., Gutierrez, A., Zhang, L., Sanda, T., Jette, C.A., Testa, J. R., Neuberg, D. S., Langenau, D. M. et al. (2010). T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 18, 353-366.
23. Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K. and Sander, J. D. (2013). High-frequency off-target mutagenesis induced by CRISPRCas nucleases in human cells. Nat. Biotechnol. 31, 822-826.
24. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. and Joung, J. K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279-284.
25. Götte, K., Schäfer, C., Riedel, F., Arens, N. and Hörmann, K. (2004). Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH. Oncol. Rep. 11, 17-23.
26. Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y., Dahlberg, S., Neuberg, D., Moreau, L. A., Winter, S. S. et al. (2009). High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647-650.
27. Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F. et al. (2014). Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J. Clin. Invest. 124, 644-655.
28. Heng, H. H., Liu, G., Stevens, J. B., Bremer, S. W., Ye, K. J. and Ye, C. J. (2010). Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr. Drug Targets 11, 1304-1316.
29. Hou, Y., Song, L., Zhu, P., Zhang, B., Tao, Y., Xu, X., Li, F., Wu, K., Liang, J., Shao, D. et al. (2012). Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873-885.
30. Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., Collins, J. E., Humphray, S., McLaren, K., Matthews, L. et al. (2013). The zebrafish reference genome sequence and its relationship to the human genome. Nature 496, 498-503.
31. Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C. and Schmid, B. (2013). Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 140, 4982-4987.
32. Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Kaini, P., Sander, J. D., Joung, J.K., Peterson, R. T. and Yeh, J.-R. J. (2013). Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE 8, e68708.
33. Ignatius, M. S., Chen, E., Elpek, N. M., Fuller, A. Z., Tenente, I. M., Clagg, R., Liu, S., Blackburn, J. S., Linardic, C. M., Rosenberg, A. E. et al. (2012). In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 21, 680-693.
34. Jao, L.-E., Wente, S. R. and Chen, W. (2013). Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc. Natl. Acad. Sci. USA 110, 13904-13909.
35. Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Van Wier, S., Blackburn, P. R., Baker, A. S., Dispenzieri, A. et al. (2012). Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067-1076.
36. Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M.S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L. et al. (2013). Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726.
37. Langenau, D. M., Keefe, M. D., Storer, N. Y., Jette, C. A., Smith, A. C. H., Ceol, C.J., Bourque, C., Look, A. T. and Zon, L. I. (2008). Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic Zebrafish. Oncogene 27, 4242-4248. (Pubitemid 351969909)
38. Le, X., Pugach, E. K., Hettmer, S., Storer, N. Y., Liu, J., Wills, A. A., DiBiase, A., Chen, E. Y., Ignatius, M. S., Poss, K. D. et al. (2013). A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 140, 2354-2364.
39. Li, Y., Xu, X., Song, L., Hou, Y., Li, Z., Tsang, S., Li, F., Im, K. M., Wu, K., Wu, H. et al. (2012). Single-cell sequencing analysis characterizes common and cell-lineagespecific mutations in a muscle-invasive bladder cancer. Gigascience 1, 12.
40. Livet, J., Weissman, T. A., Kang, H., Draft, R. W., Lu, J., Bennis, R. A., Sanes, J. R.and Lichtman, J. W. (2007). Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 56-62. (Pubitemid 350070576)
41. Magee, J. A., Piskounova, E. and Morrison, S. J. (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296.
42. Marusyk, A. and Polyak, K. (2010). Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105-117.
43. Melchor, L., Brioli, A., Wardell, C. P., Murison, A., Potter, N. E., Kaiser, M. F., Fryer, R. A., Johnson, D. C., Begum, D. B., Hulkki Wilson, S. et al. (2014). Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia.
44. Moore, F. E., Reyon, D., Sander, J. D., Martinez, S. A., Blackburn, J. S., Khayter, C., Ramirez, C. L., Joung, J. K. and Langenau, D. M. (2012). Improved somatic mutagenesis in zebrafish using transcription activator-like effector nucleases (TALENs). PLoS ONE 7, e37877.
45. Morrison, C. D., Liu, P., Woloszynska-Read, A., Zhang, J., Luo, W., Qin, M., Bshara, W., Conroy, J. M., Sabatini, L., Vedell, P., et al. (2014). Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl. Acad. Sci. USA [Epub ahead of print] doi:10.1073/pnas.1313580111.
46. Mudbhary, R., Hoshida, Y., Chernyavskaya, Y., Jacob, V., Villanueva, A., Fiel, M. I., Chen, X., Kojima, K., Thung, S., Bronson, R. T., et al. (2014). UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196-209.
47. Mullighan, C. G., Phillips, L. A., Su, X., Ma, J., Miller, C. B., Shurtleff, S. A. and Downing, J. R. (2008). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380. (Pubitemid 352775249)
48. Murugaesu, N., Chew, S. K. and Swanton, C. (2013). Adapting clinical paradigms to the challenges of cancer clonal evolution. Am. J. Pathol. 182, 1962-1971.
49. Navin, N., Krasnitz, A., Rodgers, L., Cook, K., Meth, J., Kendall, J., Riggs, M., Eberling, Y., Troge, J., Grubor, V. et al. (2010). Inferring tumor progression from genomic heterogeneity. Genome Res. 20, 68-80.
50. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D. et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94.
51. Pan, Y. A., Freundlich, T., Weissman, T. A., Schoppik, D., Wang, X. C., Zimmerman, S., Ciruna, B., Sanes, J. R., Lichtman, J. W. and Schier, A. F. (2013). Zebrabow: multispectral cell labeling for cell tracing and lineage analysis in zebrafish. Development 140, 2835-2846.
52. Piovan, E., Yu, J., Tosello, V., Herranz, D., Ambesi-Impiombato, A., Da Silva, A. C., Sanchez-Martin, M., Perez-Garcia, A., Rigo, I., Castillo, M. et al. (2013). Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766-776.
53. Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M. and Morrison, S. J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
54. Ridges, S., Heaton, W. L., Joshi, D., Choi, H., Eiring, A., Batchelor, L., Choudhry, P., Manos, E. J., Sofla, H., Sanati, A. et al. (2012). Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 119, 5621-5631.
55. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Laï, J.-L., Philippe, N., Facon, T., Fenaux, P. and Preudhomme, C. (2002). Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018. (Pubitemid 34832631)
56. Rudner, L. A., Brown, K. H., Dobrinski, K. P., Bradley, D. F., Garcia, M. I., Smith, A.C. H., Downie, J. M., Meeker, N. D., Look, A. T., Downing, J. R. et al. (2011). Shared acquired genomic changes in zebrafish and human T-ALL. Oncogene 30, 4289-4296.
57. Sander, J. D., Dahlborg, E. J., Goodwin, M. J., Cade, L., Zhang, F., Cifuentes, D., Curtin, S. J., Blackburn, J. S., Thibodeau-Beganny, S., Qi, Y. et al. (2011). Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat. Methods 8, 67-69.
58. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J. and Sawyers, C. L. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125. (Pubitemid 41039112)
59. Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G. et al. (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399.
60. Smith, A. C. H., Raimondi, A. R., Salthouse, C. D., Ignatius, M. S., Blackburn, J.S., Mizgirev, I. V., Storer, N. Y., de Jong, J. L. O., Chen, A. T., Zhou, Y. et al. (2010). High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood 115, 3296-3303.
61. Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K. D., Betensky, R. A. et al. (2011). Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817.
62. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
63. Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L. et al. (2012). Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30, 433-440.
64. Suster, M. L., Kikuta, H., Urasaki, A., Asakawa, K. and Kawakami, K. (2009). Transgenesis in zebrafish with the tol2 transposon system. Methods Mol. Biol. 561, 41-63.
65. Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A. et al. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14, 461-471.
66. Swanton, C. (2012). Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875-4882.
67. Teixeira, M. R., Pandis, N., Bardi, G., Andersen, J. A. and Heim, S. (1996). Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 56, 855-859. (Pubitemid 26055477)
68. Trede, N. S., Heaton, W., Ridges, S., Sofla, H., Cusick, M., Bearss, D., Jones, D. and Fujinami, R. S. (2013). Discovery of biologically active oncologic and immunologic small molecule therapies using zebrafish: overview and example of modulation of T cell activation. Curr. Protoc. Pharmacol. 60, 14.24.1-14.24.13.
69. White, R., Rose, K. and Zon, L. (2013). Zebrafish cancer: the state of the art and the path forward. Nat. Rev. Cancer 13, 624-636.
70. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A. et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117.
71. Yeh, J.-R. J., Munson, K. M., Elagib, K. E., Goldfarb, A. N., Sweetser, D. A. and Peterson, R. T. (2009). Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat. Chem. Biol. 5, 236-243.
72. Zhang, G., Hoersch, S., Amsterdam, A., Whittaker, C. A., Lees, J. A. and Hopkins, N. (2010). Highly aneuploid zebrafish malignant peripheral nerve sheath tumors have genetic alterations similar to human cancers. Proc. Natl. Acad. Sci. USA 107, 16940-16945.
73. Zhang, G., Hoersch, S., Amsterdam, A., Whittaker, C. A., Beert, E., Catchen, J. M., Farrington, S., Postlethwait, J. H., Legius, E., Hopkins, N. et al. (2013). Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery. PLoS Genet. 9, e1003734.
74. Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H. et al. (2012). Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 21, 362-373.
75. Zu, Y., Tong, X., Wang, Z., Liu, D., Pan, R., Li, Z., Hu, Y., Luo, Z., Huang, P., Wu, Q. et al. (2013). TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat. Methods 10, 329-331